China National Accord Medicines Corp Ltd Cash Flow Reinvestment Rate
China National Accord Medicines Corp Ltd cash flow reinvestment rate. China National Accord Medicines Corp Ltd (200028) has a Cash Flow Reinvestment Rate of 0.05x as of June 2025, reinvesting HK$95.44 Million (capex HK$50.09 Million plus investments HK$45.35 Million) from operating cash flow of HK$1.83 Billion. Explore China National Accord Medicines Corp Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of China National Accord Medicines Corp Ltd (1998–2025)
Cash flow reinvestment rate of China National Accord Medicines Corp Ltd from 1998 to 2025. Historical reinvestment intensity for China National Accord Medicines Corp Ltd across 27 annual periods. Explore 200028 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
China National Accord Medicines Corp Ltd Cash Flow Reinvestment Rate by Year (1998–2025)
China National Accord Medicines Corp Ltd cash flow reinvestment rate by year from 1998 to 2025. Year-by-year capital reinvestment analysis for China National Accord Medicines Corp Ltd. For the full cash flow conversion analysis, see 200028 cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (HKD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.21x | HK$337.47 Million | HK$1.64 Billion | HK$217.35 Million | ▲ +41.3% |
| 2024 | 0.15x | HK$476.87 Million | HK$3.27 Billion | HK$282.70 Million | ▼ -6.4% |
| 2023 | 0.16x | HK$457.64 Million | HK$2.94 Billion | HK$322.21 Million | ▼ -40.0% |
| 2022 | 0.26x | HK$665.01 Million | HK$2.56 Billion | HK$322.19 Million | ▼ -16.4% |
| 2021 | 0.31x | HK$514.46 Million | HK$1.66 Billion | HK$370.43 Million | ▲ +43.8% |
| 2020 | 0.22x | HK$324.92 Million | HK$1.50 Billion | HK$293.83 Million | ▲ +43.6% |
| 2019 | 0.15x | HK$301.17 Million | HK$2.00 Billion | HK$245.17 Million | ▼ -47.6% |
| 2018 | 0.29x | HK$380.06 Million | HK$1.32 Billion | HK$255.48 Million | ▲ +70.1% |
| 2017 | 0.17x | HK$217.09 Million | HK$1.29 Billion | HK$204.35 Million | ▼ -9.6% |
| 2016 | 0.19x | HK$275.02 Million | HK$1.47 Billion | HK$265.89 Million | ▼ -13.7% |
| 2015 | 0.22x | HK$226.73 Million | HK$1.05 Billion | HK$190.36 Million | ▼ -33.1% |
| 2013 | 0.32x | HK$150.50 Million | HK$465.03 Million | HK$150.50 Million | ▼ -45.8% |
| 2012 | 0.60x | HK$193.57 Million | HK$323.96 Million | HK$193.57 Million | ▼ -31.7% |
| 2011 | 0.88x | HK$198.97 Million | HK$227.32 Million | HK$198.97 Million | ▲ +110.6% |
| 2010 | 0.42x | HK$177.99 Million | HK$428.16 Million | HK$177.99 Million | ▲ +9.4% |
| 2009 | 0.38x | HK$102.94 Million | HK$270.85 Million | HK$102.94 Million | ▲ +10.3% |
| 2008 | 0.34x | HK$84.98 Million | HK$246.58 Million | HK$84.98 Million | ▼ -57.7% |
| 2007 | 0.81x | HK$71.41 Million | HK$87.70 Million | HK$71.41 Million | ▲ +25.2% |
| 2006 | 0.65x | HK$118.22 Million | HK$181.73 Million | HK$118.22 Million | ▲ +90.5% |
| 2005 | 0.34x | HK$50.62 Million | HK$148.28 Million | HK$50.62 Million | ▲ +213.6% |
| 2004 | 0.11x | HK$14.18 Million | HK$130.30 Million | HK$14.18 Million | ▼ -82.1% |
| 2003 | 0.61x | HK$49.36 Million | HK$81.22 Million | HK$49.36 Million | ▼ -35.0% |
| 2002 | 0.94x | HK$26.90 Million | HK$28.76 Million | HK$26.90 Million | ▲ +85.3% |
| 2001 | 0.50x | HK$35.91 Million | HK$71.16 Million | HK$35.91 Million | ▼ -79.5% |
| 2000 | 2.47x | HK$21.01 Million | HK$8.52 Million | HK$21.01 Million | ▲ +104.6% |
| 1999 | 1.21x | HK$27.54 Million | HK$22.84 Million | HK$27.54 Million | ▼ -39.5% |
| 1998 | 1.99x | HK$10.38 Million | HK$5.21 Million | HK$10.38 Million | — |